Tag: Zoll

ZOLL Enrolls First Patient in Groundbreaking SSCORE Commercial Registry at Minneapolis Heart Institute at Abbott Northwestern Hospital (Minneapolis, MN)

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has been enrolled in the SuperSaturated oxygen Comprehensive Observational REgistry (SSCORE). The prospective study is designed to provide further evidence of the efficacy […]

Late-breaking Analysis From the remedē® System Pivotal Trial Suggests Favorable Outcomes for Heart Failure (HF) Patients With Central Sleep Apnea Receiving Phrenic Nerve Stimulation

May 13, 2024 09:28 AM Eastern Daylight Time CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for […]

First Patient Enrolled in REAL SSO2 Study to Evaluate Clinical Utility and Economic Value of ZOLL TherOx SSO2 Therapy

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard […]

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for TherOx SuperSaturated Oxygen Therapy

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, […]

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

Study Evaluates the Effectiveness of TherOx Supersaturated Oxygen (SSO2) Therapy in Patients Presenting with Acute Anterior Myocardial Infarction with Successful Reperfusion Compared to Standard Therapy CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software […]

ZOLL Launches Next Generation MCT Solution, Shown to Improve Patient Management Decisions in Largest Ever MCT Trial

The ZOLL Arrhythmia Management System (AMS) mobile cardiac telemetry (MCT) solution adds biometric data to traditional MCT data, helping physicians make more informed treatment plans CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software […]

American Medical Association Issues New Category III CPT Code for ZOLL Medical’s TherOx SSO2 Therapy

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT® code, effective July 1, 2021, for its TherOx® SuperSaturated […]

ZOLL Medical Receives FDA IDE Approval for Initiation of ISO Shock (Incorporating Supersaturated Oxygen in Shock) Feasibility Study

Study Evaluates the Safety and Feasibility of TherOx Supersaturated Oxygen (SSO2) Therapy in STEMI Patients presenting with Cardiogenic Shock CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today the U.S. […]